Abstract TP048: Body Weight-Adapted Fibrinolysis Dosing Schemes in Acute Ischemic Stroke and ST-Elevation Myocardial Infarction: A Risk–Benefit Analysis

Introduction: Body weight (BW)-adapted dosing schemes for tenecteplase (TNK) and alteplase (ALT) vary. Determining whether dosing schemes affect efficacy and safety outcomes is key to facilitating treatment in emergencies where precise weight measurement is often not possible. We conducted a post hoc analysis of two BW dosing schemes (mg/kg dosing vs 10 kg BW categories) using TNK and ALT data from acute ischemic stroke (AIS) and ST-elevation myocardial infarction (STEMI) trials. Methods: Patient-level data from the STTC meta-analysis, in which ALT was dosed in mg/kg, were stratified into 10 kg BW categories used in the AcT trial (